BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 8, 2006
View Archived Issues
Incyte presents highlights of quarter
Read More
Taligen achieves Series A milestone with in vivo efficacy of TA-106
Read More
IVI to study CholeraGarde in funded program
Read More
SPA agreement for phase II study of pralatrexate in peripheral T-cell lymphoma
Read More
Neuren selects new compound for Parkinson's disease
Read More
Successful end of phase II meeting for cetilistat
Read More
Abuse-resistant opioid PTI-202 begins clinical testing
Read More
ISTA inlicenses North American rights to ophthalmic bepotastine
Read More
V-3381 studied in phase IIa trial for diabetic neuropathic pain
Read More
Advate receives Health Canada approval
Read More
Competact receives European approval for diabetes
Read More
AEterna Zentaris licenses ozarelix to Nippon Kayaku in Japan
Read More
Sphingosome encapsulated vinorelbine studied in advanced solid tumors
Read More
Sitagliptin begins phase III diabetes studies in Japan
Read More
Ceftaroline shows excellent clinical, microbiological cure rates for cSSSI
Read More
Terlipressin fails to meet primary endpoint in type 1 hepatorenal syndrome study
Read More
Ozarelix dosage regimen identified for continuous suppression of testosterone
Read More
Novel amidine analogue of melphalan exhibits more potent cytotoxicity in breast cancer cell lines
Read More
New antidiabetic agents disclosed in recent patent literature
Read More
New compounds with potential use in cancer treatment covered in recent patent literature
Read More
Recent patents describe novel agents for obesity, hypercholesterolemia, etc.
Read More
Betaseron approved in Canada for earliest stages of MS
Read More
Antidote for isotope intoxication reported by Department of Atomic Energy in India
Read More
Targeting 5-HT6 receptors with E-6837: a novel approach for the management of obesity
Read More
Novel CB1 receptor antagonist shows antiobesity potential in vivo
Read More